Stimulation of glucose and amino acid transport and activation of the insulin signaling pathways by insulin lispro in L6 skeletal muscle cells.

Abstract:

:The monomeric insulin analogue insulin lispro (Lys B28, Pro B29) is a rapid-acting insulin with a shorter duration of activity than human regular insulin. This compound has the advantage of reducing early postprandial hyperglycemia and the accompanying late hypoglycemia, thereby improving overall blood glucose control. To date, all published studies of the functional properties of insulin lispro have been conducted in whole animals. This study aimed to characterize the cellular actions of insulin lispro and the signals it elicits in an insulin-sensitive muscle cell line, L6 cells. Comparing the cellular actions of insulin lispro with those of human regular insulin, a number of observations were made. (1) Insulin lispro stimulated glucose and amino acid transport into L6 myotubes with a dose dependency and time course virtually identical to those of human regular insulin. (2) Insulin lispro was as effective as human regular insulin in stimulating time-dependent phosphorylation of insulin receptor substrate 1 (IRS-1), p70 ribosomal S6 kinase, and two isoforms of mitogen-activated protein kinase (ERK1 and ERK2). (3) Insulin lispro's ability to induce the association of IRS-1 with the p85 subunit of phosphatidylinositol 3-kinase was similar to that of human regular insulin. (4) As with human regular insulin, 100 nmol of the fungal metabolite wortmannin completely inhibited insulin lispro stimulation of glucose uptake. We concluded that the cellular actions of insulin lispro are similar to those of human regular insulin with respect to glucose and amino acid uptake and that the biochemical signals elicited are also comparable.

journal_name

Clin Ther

journal_title

Clinical therapeutics

authors

Somwar R,Sweeney G,Ramlal T,Klip A

doi

10.1016/s0149-2918(98)80040-4

subject

Has Abstract

pub_date

1998-01-01 00:00:00

pages

125-40

issue

1

eissn

0149-2918

issn

1879-114X

pii

S0149-2918(98)80040-4

journal_volume

20

pub_type

杂志文章
  • Pharmacokinetics and tolerability of extended-release clarithromycin.

    abstract:BACKGROUND:Clarithromycin is a semisynthetic macrolide that exhibits broad-spectrum activity against gram-positive, gram-negative, and atypical respiratory tract and skin/skin structure pathogens, Mycobacterium species, and Helicobacter pylori. It is indicated for the treatment of a wide variety of respiratory and derm...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/s0149-2918(01)80060-6

    authors: Guay DR,Gustavson LE,Devcich KJ,Zhang J,Cao G,Olson CA

    更新日期:2001-04-01 00:00:00

  • Pharmacokinetic interactions between eperisone hydrochloride and aceclofenac: a randomized, open-label, crossover study of healthy Korean men.

    abstract:BACKGROUND:Eperisone hydrochloride, a centrally acting muscle relaxant, is a calcium antagonist that causes vasodilation and antispastic actions. Aceclofenac, an anti-inflammatory analgesic and antipyretic drug, has similar efficacy and improved gastrointestinal tolerance compared with other nonsteroidal anti-inflammat...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.clinthera.2013.08.012

    authors: Kim MJ,Lim HS,Noh YH,Kim YH,Choi HY,Park KM,Kim SE,Bae KS

    更新日期:2013-10-01 00:00:00

  • Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States.

    abstract:BACKGROUND:Alzheimer's disease (AD) is estimated to affect up to 11% of those aged > or =65 years in the United States, and the number of patients with AD is predicted to increase over the next few decades as the population ages. The substantial social and economic burden associated with AD is well established, with th...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/s0149-2918(03)80171-6

    authors: Migliaccio-Walle K,Getsios D,Caro JJ,Ishak KJ,O'Brien JA,Papadopoulos G,AHEAD Study Group.

    更新日期:2003-06-01 00:00:00

  • Results of a cross-sectional survey about lipid-management practices among cardiologists in Pakistan: assessment of adherence to published treatment guidelines.

    abstract:OBJECTIVES:The aims of this study were to assess how closely cardiologists in Pakistan followed published recommendations for lipid management and to identify the factors associated with such behavior. METHODS:A cross-sectional survey was delivered in person between September and December 2007 to all cardiologists pra...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2009.07.020

    authors: Gowani SA,Shoukat S,Taqui AM,Bhulani N,Khalid S,Sheikh A,Halim MS,Samreen S,Jafary FH

    更新日期:2009-07-01 00:00:00

  • Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled

    abstract:BACKGROUND:Although the metabolic effects of the thiazolidinediones have been well studied, there is a lack of comparative data on their effects on certain cardiovascular risk factors, such as elevated plasma levels of lipoprotein (a) (Lp[a]) and homocysteine (Hcy). OBJECTIVE:This study compared the effects of pioglit...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.clinthera.2006.05.012

    authors: Derosa G,Cicero AF,D'Angelo A,Gaddi A,Ciccarelli L,Piccinni MN,Salvadeo SA,Pricolo F,Ferrari I,Gravina A,Ragonesi PD

    更新日期:2006-05-01 00:00:00

  • Management of Spastic Paresis and Cervical Dystonia: Access to Therapeutic Innovations Through an International Program of Practical Courses.

    abstract:PURPOSE:Our purpose was to determine satisfaction and confidence of the Ixcellence Network training program on health care practitioners using botulinum toxin A (BoNT-A) for neurologic disorders, including spastic paresis and cervical dystonia. METHODS:The Ixcellence Network training program was designed by a scientif...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2019.09.007

    authors: Colosimo C,Bhidayasiri R,Fheodoroff K,Bhatia K,Chung TM,Landreau T,Jacinto LJ

    更新日期:2019-11-01 00:00:00

  • Drug use and prescribing problems in the community-dwelling elderly: a study of three state Medicaid programs.

    abstract::This paper describes a study of drug use and drug-related problems in community-dwelling elderly (> or =65 years) Medicaid recipients in Maryland, Iowa, and Washington from 1989 through 1996. A claim-by-claim review of Medicaid prescriptions was conducted to detect 5 types of prescribing problems (dose, duration of th...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/s0149-2918(00)87245-8

    authors: Briesacher BA,Stuart B,Peluso R

    更新日期:1999-12-01 00:00:00

  • Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1.

    abstract::Hydroxychloroquine (HCQ), an antimalarial agent used to treat patients with autoimmune diseases, has been shown to suppress human immunodeficiency virus type 1 (HIV-1) replication in T cells and monocytes in vitro by inhibiting posttranscriptional modification of the virus. An initial randomized, placebo-controlled cl...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/s0149-2918(97)80045-8

    authors: Sperber K,Chiang G,Chen H,Ross W,Chusid E,Gonchar M,Chow R,Liriano O

    更新日期:1997-09-01 00:00:00

  • Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers.

    abstract:BACKGROUND:Empagliflozin is a sodium glucose cotransporter 2 inhibitor in clinical development as a treatment for type 2 diabetes mellitus. OBJECTIVE:The goal of this study was to investigate potential drug-drug interactions between empagliflozin and verapamil, ramipril, and digoxin in healthy volunteers. METHODS:The...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.clinthera.2013.02.015

    authors: Macha S,Sennewald R,Rose P,Schoene K,Pinnetti S,Woerle HJ,Broedl UC

    更新日期:2013-03-01 00:00:00

  • Synergistic aerobic and anaerobic infections.

    abstract::Encapsulation affects the virulence and survival of anaerobic bacteria and their protection from phagocytosis. More encapsulated Bacteroides strains and anaerobic and facultative gram-positive cocci are isolated from patients with clinical infections than from healthy people. The pathogenicity of Bacteroides, Fusobact...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:

    authors: Brook I

    更新日期:1987-01-01 00:00:00

  • A Phase I Study to Show the Relative Bioavailability and Bioequivalence of Fixed-Dose Combinations of Ambrisentan and Tadalafil in Healthy Subjects.

    abstract:PURPOSE:Pulmonary arterial hypertension (PAH) is a life-threatening disease that typically causes shortness of breath and exercise intolerance. Combination therapy with ambrisentan and tadalafil has proven to be more effective at preventing clinical failure events in patients with PAH than either drug alone. The aim of...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.clinthera.2019.04.007

    authors: Okour M,Puri A,Chen G,Port K,Berni A,Khindri S,Schneider I,Tenero D

    更新日期:2019-06-01 00:00:00

  • Albendazole in the treatment of intestinal helminthiasis in children.

    abstract::One hundred sixteen children between 2 and 15 years of age entered a clinical trial of albendazole after examination of their stools revealed ova of one or more intestinal helminths. The drug was administered as a single 400-mg dose (20 ml of 2% suspension) to all the patients except those having Hymenolepis nana infe...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:

    authors: Prasad R,Mathur PP,Taneja VK,Jagota SC

    更新日期:1985-01-01 00:00:00

  • Comparison of once-daily cephalosporin regimens for community-acquired lower respiratory tract infections in patients with chronic lung disease.

    abstract::The efficacy of cefonicid and of ceftriaxone, administered once daily for the treatment of lower respiratory tract bacterial infections (pneumonia or bronchitis), was evaluated and compared in 118 patients with chronic lung disease. The patients were randomly assigned to receive 1 gm of either drug, intravenously or i...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: McCabe RE,Schlossberg D,Donowitz GR,Scheld WM,Zellner SR,Lindenberg LB,Armstrong JH,Ein ME

    更新日期:1989-05-01 00:00:00

  • Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.

    abstract:BACKGROUND:Biosimilars are defined as biologic products that are highly similar to reference products, notwithstanding minor differences in clinically inactive components, with no clinically meaningful differences between the biologic product and the reference product in terms of safety profile, purity, and potency. Du...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2011.12.005

    authors: Ahmed I,Kaspar B,Sharma U

    更新日期:2012-02-01 00:00:00

  • Solving the antidepressant efficacy question: effect sizes in major depressive disorder.

    abstract:BACKGROUND:Numerous reviews and meta-analyses of the antidepressant literature in major depressive disorders (MDD), both acute and maintenance, have been published, some claiming that antidepressants are mostly ineffective and others that they are mostly effective, in either acute or maintenance treatment. OBJECTIVE:T...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2011.11.019

    authors: Vöhringer PA,Ghaemi SN

    更新日期:2011-12-01 00:00:00

  • Overview of US Maternal Mortality Policy.

    abstract::The United States maternal mortality rate has been rising for many years putting the US out of step with peer countries. There are many complex reasons for the rise in maternal deaths and recent data has demonstrated that there is a disproportionate risk for women of color. This article provides an overview of current...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2020.01.015

    authors: Villavicencio JC,McHugh KW,Edmonds BT

    更新日期:2020-03-01 00:00:00

  • Opioid interruptions, pain, and withdrawal symptoms in nursing home residents.

    abstract:PURPOSE:Interruptions in opioid use have the potential to cause pain relapse and withdrawal symptoms. The objectives of this study were to observe patterns of opioid interruption during acute illness in nursing home residents and examine associations between interruptions and pain and withdrawal symptoms. METHODS:Pati...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2014.10.013

    authors: Redding SE,Liu S,Hung WW,Boockvar KS

    更新日期:2014-11-01 00:00:00

  • COVID-19: Regulatory Landscape of Medicinal and Medical Device Products for Human Use.

    abstract::Against the backdrop of the COVID pandemic, the scientific and medical communities are working with all deliberate speed with state-of-the-art technologies to develop diagnostic and therapeutic products that can identify, treat, and prevent infection with SARS-CoV-2. These activities may only be legally conducted with...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2020.06.014

    authors: Beninger P

    更新日期:2020-08-01 00:00:00

  • Efficacy of long-term treatment with nipradilol, a nitroester-containing beta-blocker, in patients with mild-to-moderate essential hypertension.

    abstract::The effects of long-term treatment with nipradilol, a nitroester-containing beta-blocker, on casual and 24-hour blood pressures were studied in 70 patients with mild-to-moderate essential hypertension. Antihypertensive effects of nipradilol on casual blood pressure were observed in 68% of patients. Nipradilol reduced ...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1016/0149-2918(95)80043-3

    authors: Haneda T,Ogawa Y,Akaishi T,Takeda H,Tanazawa S,Inoue H,Ohki Y,Kato J,Morimoto H,Kanaya K

    更新日期:1995-07-01 00:00:00

  • Unsuccessful cimetidine treatment of peptic ulcer: analysis of the factors involved.

    abstract::Healing rates were examined retrospectively in 124 outpatients with peptic ulcer who had received cimetidine for at least four weeks. Treatment was unsuccessful in 73 patients. A statistical analysis of the factors involved in treatment failure revealed that in patients with duodenal ulcers 60.6% of the treatment succ...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:

    authors: Granelli P,Angelini GP,Celli L

    更新日期:1984-01-01 00:00:00

  • Conscientious objection and abortifacient drugs.

    abstract::The legal right to assert a conscientious objection is reviewed, using as an example the dispensing of abortifacient drugs by pharmacists. The three areas of law that most significantly concern the right to assert a conscientious refusal are employment law, conscience clauses, and religious discrimination law. Each of...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:

    authors: Brushwood DB

    更新日期:1993-01-01 00:00:00

  • Current and emerging therapies for Alzheimer's disease.

    abstract::Alzheimer's disease (AD) is a devastating neurodegenerative disorder, with a rapidly increasing worldwide prevalence. Although no cure for AD has yet been found, substantial progress has been made in our understanding of AD pathogenesis. This progress has led to the development of numerous promising compounds in vario...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2013.09.009

    authors: Nygaard HB

    更新日期:2013-10-01 00:00:00

  • Management of worsening multiple sclerosis with mitoxantrone: a review.

    abstract:BACKGROUND:Mitoxantrone, an intravenously administered immunosuppressant that inhibits T-cell, B-cell, and macrophage proliferation, is indicated for reducing neurologic disability and relapse frequency in patients with secondary progressive multiple sclerosis (SPMS), progressive relapsing MS, or worsening relapsing-re...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2006.04.013

    authors: Fox EJ

    更新日期:2006-04-01 00:00:00

  • Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.

    abstract:BACKGROUND:Treatment with interferon-beta (IFN-beta) has been related to worsening of muscle spasticity in patients with multiple sclerosis (MS). However, there are no specific data on the effects of glatiramer acetate (GA) on spasticity. OBJECTIVE:The aim of the present study was to assess the effects of GA on spasti...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.clinthera.2010.06.005

    authors: Meca-Lallana JE,de Mingo-Casado P,Amorin-Díaz M,Martínez-Navarro ML,Barreiro AF

    更新日期:2010-06-01 00:00:00

  • Multidisciplinary management of chronic heart failure: principles and future trends.

    abstract:PURPOSE:Globally, the management of chronic heart failure (CHF) challenges health systems. The high burden of disease and the costs associated with hospitalization adversely affect individuals, families, and society. Improved quality, access, efficiency, and equity of CHF care can be achieved by using multidisciplinary...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2015.08.021

    authors: Davidson PM,Newton PJ,Tankumpuan T,Paull G,Dennison-Himmelfarb C

    更新日期:2015-10-01 00:00:00

  • Effect of 24 weeks of treatment with epalrestat, an aldose reductase inhibitor, on peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus.

    abstract::The effects of treatment with epalrestat, an aldose reductase inhibitor, on peripheral neuropathy were studied in 45 patients with non-insulin-dependent diabetes mellitus (NIDDM). Epalrestat 150 mg three times daily was given for 24 weeks. Subjective symptoms, such as spontaneous pain in the lower extremities and numb...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1016/0149-2918(95)80111-1

    authors: Uchida K,Kigoshi T,Nakano S,Ishii T,Kitazawa M,Morimoto S

    更新日期:1995-05-01 00:00:00

  • Effects of lisuride hydrogen maleate on ischemia-induced depletion of brain acetylcholine levels in gerbils.

    abstract::Effects of several cerebral metabolic activators on ischemia-induced decrease in brain acetylcholine levels were studied in gerbils. Single administration of lisuride hydrogen maleate (lisuride) significantly inhibited ischemia-induced decreases in acetylcholine in the hippocampus among various regions of the brain in...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:

    authors: Ogawa N,Haba K,Yoshikawa H,Kawata M,Sato H

    更新日期:1989-03-01 00:00:00

  • Ensuring health care quality: a purchaser's perspective--a health care coalition.

    abstract::This paper explores how one health care purchasing coalition in Minnesota, the Buyers Health Care Action Group (BHCAG), has taken an active role in restructuring its local health care market. BHCAG started with the belief that the consumer should be the motivating force in health care delivery. Unfortunately, providin...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:

    authors: Robinow A

    更新日期:1997-11-01 00:00:00

  • Cost-effectiveness of everolimus for second-line treatment of metastatic renal cell carcinoma in Serbia.

    abstract:BACKGROUND:New targeted therapeutics for metastatic renal cell carcinoma (mRCC) enable an increment in progression-free survival (PFS) ranging from 2 to 6 months. Compared with best supportive care, everolimus demonstrated an additional PFS of 3 months in patients with mRCC whose disease had progressed on sunitinib and...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2013.10.004

    authors: Mihajlović J,Pechlivanoglou P,Sabo A,Tomić Z,Postma MJ

    更新日期:2013-12-01 00:00:00

  • Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.

    abstract:BACKGROUND:Gastrointestinal (GI) symptoms and high dosing frequency have been cited as reasons for inadequate adherence to daily or weekly oral bisphosphonate therapy. Inadequate adherence may lead to poor therapeutic outcomes. OBJECTIVE:The PRIOR study evaluated adherence to and GI tolerability of monthly therapy wit...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1016/j.clinthera.2008.04.009

    authors: Lewiecki EM,Babbitt AM,Piziak VK,Ozturk ZE,Bone HG

    更新日期:2008-04-01 00:00:00